CROs/Service Providers

Ark Therapeutics signs a letter of intent with EMD Millipore

Friday, August 17, 2012 11:13 AM

Ark Therapeutics, a London-based contract development and manufacturing company focused on viral product, has signed a non-binding letter of intent with EMD Millipore, a division of Merck, to enter into a collaborative agreement in the field of viral based bioengineered vaccines and other live viral products manufacturing. 

More... »

INC Research promotes Macdonald to CEO, Ogle to continue as chairman

Friday, August 17, 2012 07:42 AM

Raleigh, N.C.-based INC Research, a therapeutically focused CRO has, as part of a planned succession, promoted Chief Operating Officer Jamie Macdonald to president and Chief Executive Officer. Chairman and CEO James T. Ogle will continue to serve as chairman.

More... »

IMS Health expands suite of syndicated analytics with PharmaDeals acquisition

Wednesday, August 15, 2012 11:22 AM

IMS Health, a provider of information, services and technology for the healthcare industry, has acquired PharmaDeals, a provider of online information about business transactions, licensing, and mergers and acquisitions activity within the global pharmaceutical industry.

More... »

Six pharmas employing Epic Sciences’ circulating tumor cell technology

Wednesday, August 15, 2012 10:38 AM

Epic Sciences, a privately held cancer diagnostics company of La Jolla, Calif., has established collaborations with six pharmaceutical partners employing Epic’s proprietary Circulating Tumor Cell (“CTC”) technology.

More... »

Quintiles acquires Expression Analysis to advance personalized medicine

Monday, August 13, 2012 12:02 PM

Quintiles, a fully integrated biopharmaceutical services company, has acquired Expression Analysis (EA), a Durham, N.C.-based provider of genomics testing and analysis to biopharma, academic, government and non-profit customers. Terms of the transaction were not disclosed.

More... »

Pluristem, Cato Research collaborate on intermittent claudication

Monday, August 13, 2012 11:32 AM

Pluristem Therapeutics, a developer of placenta-based cell therapies based in Israel, has selected Cato Research as its CRO for the German portion of the company's phase II trial in intermittent claudication (IC) under the auspices of the Paul-Ehrlich Institute (PEI).

More... »

CareSouth's expands in Florida, creates jobs in Georgia

Friday, August 10, 2012 12:50 PM

CareSouth Health System, a provider of non-acute care, has expanded its health care services throughout Florida with the purchase of key assets of Alliance Care, a provider of home health care, private duty and physician house call services.

More... »

Almac enhances service offering in refrigerated storage

Wednesday, August 8, 2012 11:38 AM

Almac, a global service provider based in Ireland, has further enhanced its service offering with the completed expansion of refrigerated (2-8°C) storage and newly developed refrigerated labelling facilities at its U.K. site. 

More... »

DKSH divests contract manufacturing plant OLIC to Fuji Pharma

Wednesday, August 8, 2012 10:47 AM

DKSH, a market expansion services provider with a focus on Asia, has agreed to divest OLIC, a contract manufacturing operation of pharmaceutical products in Thailand, to Fuji Pharma of Japan. The transaction is subject to customary closing conditions.

More... »

Icon to expand hospital-based presence in translational medicine

Wednesday, August 8, 2012 10:26 AM

Icon, a global provider of outsourced development services, has announced plans to further expand its U.K. hospital-based presence on the Manchester Royal Infirmary Campus.

More... »